{"id":56945,"date":"2024-02-27T17:15:28","date_gmt":"2024-02-27T17:15:28","guid":{"rendered":"https:\/\/medsname.com\/etova\/"},"modified":"2026-05-01T10:49:13","modified_gmt":"2026-05-01T10:49:13","slug":"etova","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/etova\/","title":{"rendered":"Etova"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Etova?<\/h3>\n

Etova<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 etodolac<\/strong> \u03b4\u03b9\u03c3\u03ba\u03af\u03bf \u03b4\u03b9\u03b1\u03b8\u03ad\u03c3\u03b9\u03bc\u03bf \u03c3\u03b5 200 mg and 400 mg<\/strong> strengths. Etodolac is a preferential COX-2 NSAID<\/strong> — at therapeutic doses it blocks the inflammation-driving COX-2 enzyme more than the stomach-protective COX-1, giving a modestly gentler GI profile than diclofenac, ibuprofen, or naproxen. The usual adult dose is 200–400 mg twice daily with food<\/strong>. Etova is widely used for osteoarthritis, rheumatoid arthritis, acute musculoskeletal pain, and post-operative pain.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

Etova<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03b4\u03b9\u03c3\u03ba\u03ce\u03b4\u03b9\u03bf \u03b3\u03b9\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 etodolac<\/strong>, a second-generation NSAID marketed by Ipca Laboratories. Etodolac belongs to the pyranocarboxylic-acid class and has a documented 5–10 fold preference for COX-2 over COX-1<\/strong> at clinical doses. This places it between classical non-selective NSAIDs (ibuprofen, diclofenac) and highly selective COX-2 inhibitors (celecoxib), with a generally intermediate risk profile.<\/p>\n

Etodolac’s 7-hour half-life allows simple twice-daily dosing, and the preferential COX-2 activity means fewer reports of indigestion, gastritis, and peptic ulcer disease than with non-selective NSAIDs at equivalent anti-inflammatory effect.<\/p>\n

What Is Etova Used For?<\/h2>\n
    \n
  • Osteoarthritis<\/strong> — joint pain, stiffness, reduced range of movement<\/li>\n
  • Rheumatoid arthritis<\/strong> — symptomatic relief of inflammatory flares<\/li>\n
  • Acute musculoskeletal pain<\/strong> — sprains, strains, soft-tissue injury<\/li>\n
  • Post-operative pain<\/strong> — including dental, orthopaedic, and gynaecological procedures<\/li>\n
  • Low back pain<\/strong><\/li>\n
  • Ankylosing spondylitis<\/strong> — second-line option when indomethacin is not tolerated<\/li>\n
  • Primary dysmenorrhoea<\/strong><\/li>\n
  • Dental and orofacial pain<\/strong><\/li>\n<\/ul>\n

    How Does Etodolac Work?<\/h2>\n

    Etodolac has preferential COX-2 activity<\/strong> — at therapeutic doses it inhibits the inflammation-driving COX-2 enzyme more than the stomach-protective COX-1. This gives a modestly lower risk of GI ulcers than classical non-selective NSAIDs such as diclofenac, ibuprofen, and naproxen.<\/p>\n

    The therapeutic chain of events is the same for every NSAID:<\/p>\n

      \n
    1. Tissue injury or inflammation releases phospholipids from cell membranes<\/li>\n
    2. Phospholipase A₂ converts them to arachidonic acid<\/li>\n
    3. Cyclooxygenase (COX-1\/COX-2) converts arachidonic acid to prostaglandins<\/strong> — the molecules responsible for pain, swelling, and fever<\/li>\n
    4. Etodolac blocks the COX enzymes, so less prostaglandin is produced, so there is less pain and inflammation<\/li>\n<\/ol>\n

      Because prostaglandins also protect the stomach lining, regulate kidney blood flow, and influence platelet function, the same mechanism that relieves pain is also responsible for the main NSAID side effects: stomach irritation, fluid retention, high blood pressure, and (in some individuals) kidney stress.<\/p>\n

      Etova Dosing<\/h2>\n
        \n
      • Osteoarthritis, rheumatoid arthritis:<\/strong> 200–400 mg twice daily with food. Maximum 1,200 mg\/day (rarely needed).<\/li>\n
      • Acute pain, post-operative pain:<\/strong> 200–400 mg twice daily for 3–7 days.<\/li>\n
      • Elderly, low body weight (< 60 kg), renal impairment:<\/strong> start at 200 mg twice daily and titrate only if needed.<\/li>\n<\/ul>\n

        Take with food or milk to reduce GI irritation. Swallow tablets whole with water. Doses should be spaced about 12 hours apart (e.g. 8 a.m. and 8 p.m.). Miss a dose: take it when you remember unless the next is due within 4 hours — then skip.<\/p>\n

        \n

        GI safety — read this before the first dose.<\/strong> Every NSAID, including Etova, carries a real risk of gastritis, peptic ulcer, and upper-GI bleeding. The risk is highest in patients over 65, in those with prior ulcer disease, and in anyone also taking low-dose aspirin, corticosteroids, SSRIs, or anticoagulants. Take Etova with food<\/em>, use the lowest effective dose for the shortest reasonable time<\/em>, and ask your doctor about co-prescribing a proton pump inhibitor (omeprazole, pantoprazole) if you need it for more than 2–4 weeks.<\/p>\n<\/div>\n

        Who Should Not Take Etova?<\/h2>\n
          \n
        • Known hypersensitivity to Etodolac or any NSAID<\/li>\n
        • Active or recurrent peptic ulcer, GI bleed, or GI perforation<\/li>\n
        • Asthma, urticaria, or rhinitis precipitated by aspirin or another NSAID (“aspirin-exacerbated respiratory disease”)<\/li>\n
        • Severe heart failure (NYHA class IV)<\/li>\n
        • Severe hepatic impairment (Child–Pugh C)<\/li>\n
        • Severe renal impairment (CrCl < 30 mL\/min)<\/li>\n
        • Third trimester of pregnancy (risk of premature ductus arteriosus closure and oligohydramnios)<\/li>\n
        • Recent coronary artery bypass graft surgery (CABG) — absolute contraindication for all NSAIDs<\/li>\n<\/ul>\n

          \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03cc\u03c2 \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2<\/h3>\n

          All NSAIDs (except low-dose aspirin) carry some increase in the risk of heart attack and stroke, and can worsen heart failure. The risk is dose- and duration-dependent and is generally highest with COX-2 selective agents and with diclofenac. Patients with established ischaemic heart disease, peripheral arterial disease, stroke, or uncontrolled hypertension should use non-selective NSAIDs (ibuprofen or naproxen) at the lowest effective dose, or use paracetamol instead where possible.<\/p>\n

          Renal (kidney) safety<\/h3>\n

          NSAIDs reduce renal prostaglandin production, which can cause salt and water retention, raise blood pressure, and — in vulnerable patients — cause acute kidney injury. High-risk groups are the elderly, patients on ACE inhibitors\/ARBs plus diuretics (the “triple whammy”), anyone dehydrated (vomiting, diarrhoea, heat, heavy exercise), and those with pre-existing CKD. Stop the NSAID and seek medical review if you develop reduced urine output, swelling, or unexplained weight gain.<\/p>\n

          Side Effects of Etova<\/h2>\n

          Etova is generally well tolerated at standard doses.<\/p>\n